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ABSTRACT 
Deficiency of vitamin B6 due to mutations in key B6 metabolizing enzymes is suspected 
to contribute to several pathologies. Vitamin B6 in its active form, pyridoxal 5’-phosphate (PLP) 
is a cofactor for over 140 known B6 requiring (or PLP-dependent) enzymes, that serve vital roles 
in many biochemical reactions. There are three primary vitamin B6 forms, pyridoxine (PN), 
pyridoxamine (PM) and pyridoxal (PL) which are phosphorylated to pyridoxine 5’-phosphate 
(PNP), pyridoxamine 5’-phosphate (PMP) and PLP respectively. Pyridoxal kinase (PLK) and 
pyridoxine 5’-phosphate oxidase (PNPO) are the key enzymes involved in both salvage and de 
novo pathways of PLP biosynthesis. Mutations in these enzymes are one of the most important 
causes of PLP deficiency, apart from dietary insufficiency of vitamin B6 and drug inhibition of 
PLK and PNPO. One of our objectives is to understand the molecular basis of reduced catalytic 
activity of PNPO in case of the R95C homozygous missense natural mutant, which leads to the 
PLP deficiency and the debilitating disease, neonatal epilepsy encephalopathy. Using site-
directed mutagenesis, circular dichroism, enzyme kinetics and fluorescence spectroscopy, we 
have shown that the reduced enzymatic activity exhibited by PNPO R95C mutant is due to 
reduced binding affinity of the oxidase cofactor, flavin mononucleotide (FMN), which is 
required by the enzyme for oxidizing the inactive B6 vitamers into the active PLP.  
High concentrations of B6 are linked to neurotoxic effects, which can be attributed to the 
highly reactive aldehyde group of PLP which reacts with many nucleophiles in the cell. This 
reactivity is most likely why the in vivo concentration of “free” PLP is about 1 μM, raising the 
intriguing question of how the cell supplies sufficient PLP to meet the requirements of the 
xiv 
 
numerous B6 dependent enzymes. Our second objective is to determine how despite the low in 
vivo concentration of free PLP, enough of this co-factor is made available to activate PLP-
dependent enzymes. We have used affinity pull down assays, fluorescence polarization and 
enzyme kinetics to show that PNPO forms specific interactions with B6 enzymes with 
dissociation constants less than 1 µM. We also show that transfer of PLP from PNPO possibly 
occurs by compartimentalization or channeling. Although, channeling is a controversial subject, 
it offers an efficient, exclusive, and protected means of delivery of the highly reactive PLP.  
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Chapter 1 
General Introduction 
1.1 B6 vitamers:  Vitamin B6, a water soluble vitamin belonging to the B complex 
family, is critical to maintain biochemical homeostasis. There are six natural forms of vitamin 
B6: pyridoxine (PN), pyridoxal (PL), pyridoxamine (PM), and their phosphorylated analogs viz. 
pyridoxine 5’-phosphate (PNP), pyridoxal 5’-phosphate (PLP) and pyridoxamine 5’-phosphate 
(PMP), respectively.
 1,2
 (Figure 1) Of these, PLP and to a lesser extent PMP are the metabolically 
active forms that are used as cofactors by vitamin B6 dependent enzymes.
3,4
  
 
 
 
 
 
 
 
 
 
Figure 1: Structures of B6 vitamers 
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1.2 Biosynthetic pathways for vitamin B6: Prokaryotes such as bacteria synthesize 
PNP, PMP and PLP by a de novo pathway from erythrose 4-phosphate (E4P).
5
 Eukaryotes 
cannot synthesize PLP by the de novo pathway and depend on the primary dietary B6 vitamers 
PN, PL and PM for the synthesis of PLP via the so called salvage pathway. Two enzymes 
contribute to the salvage pathway: an ATP dependent pyridoxal kinase (PLK) and a flavin 
mononucleotide (FMN) dependent pyridoxine 5’-phosphate oxidase (PNPO). PLK 
phosphorylates 5’ alcohol group of PN, PL and PM to form PNP, PLP and PMP respectively. 
(Figure 2) PNP and PMP are further oxidized to PLP by PNPO.
6 
(Figure 2) PLP is then 
transferred to apo B6 dependent enzymes, which catalyze various biochemical reactions. PLP, 
PNP and PMP are dephosphorylated by phosphatase class of enzymes to PL, PN and PM 
respectively. (Figure 2) 
 
 
 
 
 
 
 
 
Figure 2: Biosynthesis of PLP 
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1.3 Pyridoxal Kinase (PLK): This ATP dependent enzyme phosphorylates 5’-alcohol of 
PM, PL and PN with γ-phosphate of ATP to form PMP, PLP and PNP respectively.
1, 8
 (Figure 3) 
The enzyme is a homodimer with one active site per subunit. Pyridoxal kinases have been 
isolated from mammalian and bacterial sources,
9, 10
 sharing 24-90% sequence homology between 
them.
11, 12
 Eukaryotic enzymes have been found to have broad substrate specificity tolerating 
modifications at the 4’-position of the vitamin B6 forms.
13, 14
 Pyridoxal kinase requires Mg
+
 or 
K
+
 for activity.
10
 
 
                                                                     
 
 
 
 
 
 
 
 
 
 
Figure 3: Phosphorylation of 5’ alcohol of PL to PLP by pyridoxal kinase 
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1.4 Pyridoxine 5’-phosphate oxidase (PNPO): This flavin mononucleotide (FMN) 
dependent enzyme catalyzes the terminal step in the de novo vitamin B6 biosynthesis in E. coli 
and is a part of the salvage pathway in E. coli and mammalian cells.
6, 15, 16
 The catalysis involves 
oxidation of 4’ hydroxyl group of PNP or 4’-amino group of PMP to form PLP. Two electrons 
are transferred to FMN, as a hydride in this process, forming FMNH2. These electrons are 
eventually transferred to molecular oxygen to form hydrogen peroxide and FMN is 
regenerated.
15, 16, 17
 (Figure 4) The enzyme is sluggish with a low catalytic rate constant ranging 
from 0.2 sec
-1 
to 0.8 sec
-1
 and Km values in the low micromolecular range for both the substrates 
PNP and PMP.
16, 17, 18
  
 
 
 
 
 
 
 
 
 
 
Figure 4: Oxidation of PNP to PLP by pyridoxine 5’-phosphate oxidase 
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PNPO is a homodimer with one active site per monomer. Each monomer (M.W. 29,985 
Da for Human enzyme) folds into an eight stranded β-sheet surrounded by five α-helical 
structures. There are two FMN binding sites at the dimer interface where the cofactor interacts 
non-covalently with both the subunits.
15, 16, 17
 (Figure 5) PNP or PMP bind at the re-face of N5 of 
the bound FMN. The isoalloxazine ring of FMN is coplanar with the pyridine ring of PNP and 
the two are separated by ~ 3.4 Å.
19
 (Figure 6) The product PLP has a greater affinity for the 
active site than either of the substrates PNP or PMP, suggesting that it function as an inhibitor of 
the enzyme.
18, 20- 23
 The human, E. coli and yeast enzymes share 54% sequence similarity, with 
28% sequence identity, but the overall structure as well as the active sites are nearly identical.
15, 
16, 24
 (Figure 7) 
Non-catalytic site for PLP: In vitro studies have shown that PNPO binds a second 
molecule of PLP tightly at a non-catalytic site. Enzymatic activities of PLP tightly complexed 
with PNPO were measured and compared with the activity of PNPO alone. PLP bound at this 
site does not inhibit the catalytic activity of the enzyme. Thus, this binding is assumed to be 
different than product inhibition by PLP which occurs at the active site. Also apo-enzyme has 
been observed to bind PLP with equal affinity as that of holo, and removal of the cofactor FMN 
did not influence binding. Even though this PLP remains bound to the enzyme during size 
exclusion chromatography it is readily transferred to apo serine hydroxymethyl transferase 
(SHMT)
16, 25
. Structural studies showed a secondary bound PLP at the surface of the protein, and 
about 11 Å from the active site.
 19
 It’s not certain whether this secondary bound PLP site is the 
functionally observed non-catalytic site. 
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Figure 5: Homodimeric structure of E. coli PNPO with FMN and PLP bound at the 
active site 
Figure 6: Active site structure of E. coli PNPO  
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Figure 7: Least square superimposition of PNPO from various sources: Human 
PNPO (red); E. coli (yellow) and yeast PNPO (cyan)  
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1.5 Vitamin B6 Dependent Enzymes: PLP serves diverse functions as a cofactor for 
over 140 vitamin B6 dependent enzymes that include oxidoreductases, transferases, isomerases, 
lyases and hydrolases, with functions of many others unknown.
26
 In addition to the catalytic 
mechanisms, reaction specificity and folding mechanisms, the 3D structures of several of these 
PLP-dependent enzymes are known.
27
 The enzymes catalyze several important biochemical 
reactions such as amino acid and lipid metabolism, carbohydrate breakdown, neurotransmitter 
synthesis, heme synthesis and nucleic acid synthesis.
26-30
 The enzymatic activities of these 
vitamin B6 dependent enzymes contribute to about 4% of all classified activities. Of particular 
interest in these is their role in brain metabolism since the synthesis of most neurotransmitters, 
including GABA (pathway A), dopamine, epinephrine, norepinephrine, serotonin (pathways B 
and C), serine (pathway D) and histamine (pathway E) involves the B6 dependent enzymes. 
(Figure 8) Concentration of PLP in brain depends on salvage pathway of synthesis since it does 
not cross the blood brain barrier easily. Since the PLP dependent enzymes compete for PLP in 
the brain, disruption of the salvage pathway could result in improper functioning of these 
enzymes. Deficiency of neurotransmitters due to improper functioning of PLP-dependent 
enzymes has been documented in several neurological disorders including epilepsy, Parkinson’s 
disease, Alzheimer’s disease and schizophrenia.
31-39
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The aldehyde functionality of PLP allows it to form Schiff linkages with the ε-amino 
group of lysine residues at the active sites of the PLP dependent enzymes, the linkages termed 
internal aldimines. The phosphate of PLP interacts with a glycine rich loop present in the active 
site. Upon binding of the amino acid substrate, the lysine is exchanged for amino group of the 
substrate which forms Schiff base with PLP. This is called external aldimine, where α-amino 
group of the amino acid substrate acts is a nucleophile that attacks the carbon of the Schiff base 
of the internal aldimine and displaces the lysine residue.
40, 41
 (Figure 9) The conversion from 
internal to external aldimine takes place via formation of a germinal diamine where PLP interacts 
with amino groups of both the substrate and the internal lysine residue. 
The PLP dependent enzymes are classified into at least 5 different classes based on amino 
acid sequence comparison, predicted secondary structure elements and available 3D structural 
information as Fold type I (e.g. aspartate aminotransferase, serine hydroxymethyl transferase, 
 
GAD: Glutamate decarboxylase, 
AAAD : Aromatic aminoacid decarboxylase
Leucine or Valine Glutamate GABA
GAD
Tyrosine DOPA Dopamine
L-5-HydroxytryptophanTryptophan Serotonin
L-Serine D-Serine
Serine 
Racemase
Histidine Histamine
A.
B.
C.
D.
E.
Tyr 
hydroxylase
Trp 
hydroxylase
AAAD
AAAD
AAAD
Figure 8: Synthesis of neurotransmitters by vitamin B6 dependent enzymes 
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threonine aldolase), Fold type II (e.g. tryptophan synthase), Fold type III (e.g. ornithine 
decarboxylase), Fold type IV (e.g. alanine aminotransferase) and finally fold type V (e.g. 
glycogen phosphorylase).
42-44
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Internal and external aldimines formed by PLP 
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1.6 Deficiency of PLP: Deficiency of isolated vitamin B6 is uncommon; it usually occurs 
in combination with deficiencies of other B-complex vitamin types. However, because of its 
wide variety of functions in the body as a cofactor, vitamin B6 deficiency results in a broad 
spectrum of impaired activities including several neurological and non neurological disorders. 
The important causes of PLP decifiency are considered as (i) dietary insufficiency, (ii) drugs or 
compounds that inhibit PLK or PNPO, the two enzymes involved in PLP metabolism, or (iii) 
impairment of PLK or PNPO due to pathogenic mutations.
45, 46
  
1.6.A Dietary insuffiency: The dietary insufficiency may produce symptoms such as 
seizures, sleeplessness, headache, restlessness, agitation, tremors, and hallucination. However, 
since vitamin B6 is present in almost all food types including potatoes, bananas, beans, seeds, 
nuts, red meat, poultry, fish, eggs, spinach, and fortified cereals, the deficiency of PLP due to 
dietary insufficiency is rare.  
1.6.B Inhibition by drugs: Some medicines as well as natural substances, on the other 
hand, have the ability to antagonize the actions of vitamin B6. Some classes of substances 
achieve the PLP antagonistic effects by inhibing activities of PLK and PNPO.
47, 48
 Acute 
inhibition of these enzymes can cause convulsions, unconsciousness, paralysis of leg and even 
death apart from the less severe symptoms such as seizures, headache and agitation.
49
 Some 
examples of drugs found to be responsible for this are ginkgotoxin (4’-O-methylpyridoxine), 
theophylline, caffeine,  theobromine, mesalamine, epinephrine and lamotrigine. For example, a 
plasma concentration of theophylline greater than 110 μM is reported to be associated with these 
symptoms.
50
 Another class of substances that are shown to cause deficiency of PLP include 
progesterone and estrogen containing oral contraceptives. These have been observed to increase 
the demand for vitamin B6 by increasing the substrate load of PLP dependent enzymes or cause 
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redistribution of PLP among its apoenzymes.
51
 Alcohol acts as a vitamin B6 inhibitor by 
decreasing the absorption of PLP.
52
 The deficiency of vitamin B6 caused by factors such as 
dietary insufficiency and drug inhibition can be treated by vitamin B6 supplements, co-
administering drugs with vitamin B6 or by stopping treatment with the vitamin B6 deficiency 
causing drugs.  
1.6.C Mutations in PLK and PNPO: A more severe deficiency of vitamin B6 can occur 
as a result of mutations in genes producing the enzymes involved in vitamin B6 metabolism. 
Human PLK and PNPO genes are situated on chromosomes 21q22.3 and 17q21.2 respectively.
53
 
In a study by Mills et al, PNPO was sequenced in patients showing deficiency of the enzyme. 
Homozygous missense, splice site and stop codon mutations were identified, all of which 
showed reduced or abolished catalytic efficiency of the enzyme, leading to PLP deficiency.
54
 
Several other studies have linked the possibility of other neurological disorders such as 
Alzheimer’s disease, schizophrenia, Parkinson’s disease, attention deficit hypersensitivity 
disorder, to the PLP deficiency due to its effect on neurotransmitter synthesis.
55, 56
 Some of the 
natural mutations observed in PLK and PNPO with their natural phenotypes are listed in Table 1. 
The use of vitamin B6 supplementation to treat PLP deficiency caused by pathogenic mutations 
in PNPO or PLK has shown conflicting results. Administration of PN alone to patients with NEE 
showed no relief, whereas administration of PL/PLP showed better results. This further supports 
the defect in PNPO. The difference between PN and PLP in seizure control has also been noted 
in a patient whose seizures were controlled by PLP but not with PN.
 
It is quite clear that therapy 
with PN or PM in patients with a defective PNPO will not be successful and administration of 
PLP as currently the most effective choice of treatment.
57
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.  
 
 
 
 
 
 
 
 
Mutation Phenotype
 
Mutation Phenotype
 
R116Q NA* P129P NA 
R229W Lethal S216F NA 
X262Q Lethal S213S None 
E50K More active R224P None 
R95C Lethal 
R95H Lethal 
Pyridoxine 5’-Phosphate Oxidase Pyridoxal Kinase 
Table 1: Mutations in PNPO and PLK along with their natural phenotypes 
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1.7 Toxicity of PLP: PLP contains a very reactive aldehyde group at the 4’ position that 
reacts with virtually all nucleophiles and proteins in the cell including non vitamin B6 dependent 
proteins, leading to neuropathies. It forms aldimines with primary and secondary amines. Some 
of the complexes formed by PLP are shown in Figure 10. It is often used as a protein labelling 
agent because of its reactivity with the ε-amino group of lysyl residues in proteins. Vitamin B6 
does not produce any toxicities at low concentrations. The current recommended dietary 
allowance of PLP is 1.3 to 2 mg/day in the United States. Toxicities are observed usually when 
the concentration exceeds 200 mg/day.
58
 The levels of B6 could be raised as a result of an 
environmental insult or genetic defects. The toxicity with PLP is known to cause sensory as well 
as motor neuropathies leading to numbness in hands and feet leading to difficulty in walking. 
Although some cases with acute, profound and permanent neuropathies have been noted, the 
sensory neuropathies are usually reversible when supplementation is stopped.
59
 Administration 
of high doses of PLP to rats and dogs has shown to produce hind leg paralysis, focal damage of 
peripheral nerves and selective degeneration of the spinal cord.
60
  
 
 
 
PLP Thiazolidine complex 
                
PLP aldimine 
                
PLP geminal diamine 
                Figure 10: Nucleophillic adducts of PLP  
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1.8 Homeostatic regulation of vitamin B6 levels: The pool of free PLP in vivo is 
maintained at a very low concentration in the body, presumably to prevent toxic buildup. 
Regulation of PLP synthesis by pyridoxal kinase and PNPO is a proposed mechanism. Zhao and 
Winkler observed inhibition of E. coli PNPO activities by product PLP with the Ki of 8 µM.
18
 In 
another study by our group, significant MgATP substrate inhibition of E. coli PLK was observed 
in presence of PNP or PLP.
12
 Another well established mechanism for maintaining low levels of 
free PLP is dephosphorylation of PLP by phosphatases. These Mg
2+
 dependent enzymes carry 
out dephosphorylation of PLP back into pyridoxal. The catalysis is carried out by both free as 
well as membrane bound phosphatases with kcat values at least 30-fold higher than the PLP 
producing enzymes. The PLP specific phosphatase has a Km of ~2.5 µM for PLP
62
. Catalytic 
conversion of pyridoxal to 4-pyridoxic acid, by aldehyde oxidase and NAD-dependent 
dehydrogenase is another mechanism of regulation of free PLP concentration
63, 64
. The 
concentration of free PLP is maintained as low as 1 µM in eukaryotic cells. Nevertheless despite 
this low level of free PLP, enough PLP is made available to vitamin B6 dependent enzymes. This 
raises the intriguing question of how the cell supplies sufficient PLP for the numerous B6 
enzymes.  
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1.9 PLP transfer: The question of how PLP adds to apo enzymes has been strongly 
debated and difficult to unravel. The problem has been noted previously by many researchers 
during their work on the enzymes involved in PLP metabolism.
22, 65, 66
 It seems that for 
successful activation of apo vitamin B6 dependent enzymes without producing any toxic effects, 
the PLP produced by B6 metabolizing enzymes should be transferred to the apo enzymes as 
quickly as possible.  
It has been studied for many years how a product or an intermediate of one enzymatic 
reaction is transferred to another enzyme to carry out subsequent reactions. Enzymes have been 
observed to follow two basic pathways by which the transfer takes place, viz. non-channeled and 
channeled. Based on these, there could be two possible mechanisms of PLP transfer to the apo 
enzymes. 
Mechanism 1: A non-channeled mechanism, where PL kinase and PNPO release PLP 
into the solution in cell and the pool of free PLP reacts with apoenzymes to activate them. 
 
 
          PNP  +  O2                                PLP                             Holo enzyme 
                                          H2O2 
However, the reactive nature of PLP, the high kcat values of phosphatases and feedback 
inhibition of the metabolising enzymes by product PLP decrease the feasibility of this route of 
transfer.  
PNPO 
Apoenzyme 
eenzyme 
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Mechanism 2: Channeled mechanism, where PLP is transferred directly from either PLK 
and PNPO to apoenzymes and activate them.  
 
 
PNP + O2                        PNPO-PLP                     PNPO-PLP-Enzyme                  Holoenzyme 
                 H2O2                                                                                        PNPO 
 
PLP transferred by this method has the advantages of shortening the reaction time and 
sequestrating the reactive PLP from bulk solution, protecting it from hydrolysis by phosphatases. 
This method of PLP transfer also prevents interaction of free PLP to enzymes and proteins other 
than B6 dependent enzymes.  
 
 
 
 
 
 
 
PNPO 
Apoenzyme 
eenzyme 
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1.10 Rationale and specific aims: Pyridoxal 5’-phosphate, the metabolically active form 
of vitamin B6, is an important cofactor for many enzymes that catalyze over 140 biochemical 
reactions, particularly reactions involved in the synthesis of neurotransmitters. Deficiency of 
PLP is therefore implicated in several neurological disorders such as neonatal epileptic 
encephalopathies, Parkinson’s disease, Alzheimer’s disease, attention deficit hypersensitivity 
disorders, Down’s syndrome to name a few. Of these, deficiency of PLP function has been 
documented in several cases of neonatal epileptic encephalopathies. The deficiency of PLP in 
NEE has been found to be mainly due to mutations in PNPO, an enzyme responsible for the 
catalysis of the terminal step of PLP synthesis. However, mutations in PLK could also be 
involved in neurological disorders. Dietary insufficiency of vitamin B6 or inhibition of PLK or 
PNPO activity by drugs are also known to result in PLP deficinecy with neurotoxic effects. Our 
first goal is to understand how a homozygous missense mutation in human PNPO, R95C affects 
its catalytic activity. 
PLP has a reactive aldehyde function which interacts with almost all nucleophiles 
including proteins other than vitamin B6 enzymes, which may cause neurological as well as non-
neurological toxicities. The in vivo concentration of free PLP is thus maintained very low (~1-2 
µM) by mechanisms such as feedback inhibition of PLK and PNPO by PLP, hydrolysis of free 
PLP back into PL by phosphatases and conversion of free PLP into 4-pyridoxic acid. It is, 
therefore, very interesting to determine how in spite of the low concentrations, PLP gets 
transferred from PNPO and PLK to the vitamin B6 dependent enzymes. Our second goal is to 
study how PLP synthesized by PNPO is transferred to the vitamin B6 dependent enzymes. 
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There are two specific aims: 
1. Determine the molecular basis of reduced activity of human pyridoxine 5’-phosphate 
oxidase due to a homozygous missense R95C mutation. 
2. Determine the mechanism of transfer of PLP from pyridoxine 5’-phophate oxidase to 
vitamin B6 dependent enzymes.  
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Chapter 2 
Molecular basis of reduced catalytic activity of human pyridoxine 
5’-phosphate oxidase by the R95C mutation 
2.1 Introduction: Neonatal epileptic encephalopathy (NEE) is a severe disorder which 
manifests a few hours after birth with intractable seizures usually unresponsive to conventional 
anticolvulsant treatment.
54
 Observed mainly in Turkish and Asian populations, NEE shows 
symptoms such as fetal distress, hypoglycemia, anemia, acidosis and asphyxia.
54, 68
 Analysis of 
cerebrospinal fluid and urine of patients shows decreased activity of vitamin B6 enzymes. The 
surviving children are usually mentally retarded and show an abnormal dependence on vitamin 
B6 in the form of pyridoxal 5’-phosphate (PLP).
69
 Studies have also shown that treatment of 
seizures resulting in NEE responded to PLP while PNP (/PMP) or PN (/PM) had no effect.
54, 68
 
This led to the suggestion that the disorder might involve defective enzymes for PLP 
biosynthesis. Sequencing of PNPO coding genes in patients with NEE have identified several 
pathogenic mutations, including homozygous missense (R95C, R95H, R229W),  stop codon 
(X262Q) or splice site (IVS3-1g > a) mutations.
57, 70-72
 Of these, our lab has previously studied 
R229W and R229Q mutations, which show highly reduced catalytic activity as compared to the 
wild type.
69
 The stop codon and splice site mutations on the other hand resulted in null PNPO 
activity. 
PNPO, the homodimeric enzyme involved in catalysis of the terminal step of PLP 
biosynthesis, has been purified from E. coli, humans, rabbit, yeast and several other species with 
the catalytic site conserved.
16
 FMN is the cofactor which is critical for the catalytic activity of 
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the enzyme and is non-covalently attached to each subunit at the dimer interface. FMN is 
coplanar with the substrate PNP and takes up two electrons in the form of a hydride from PNP to 
convert it to PLP
19, 20
.  
The present study is aimed at understanding on a molecular level why the PNPO R95C 
mutation leads to reduced oxidase activity with concomittant NEE. The catalytic site of human 
PNPO (hPNPO) is shown in Figure 11. In the wild-type structure, the Arg-95 residue forms salt 
bridge/hydrogen bond interactions with the phosphate side chain of the FMN molecule present in 
the catalytic site. Figure 11 also shows a putative position of Cys95 replacement of Arg95. We 
hypothesize that the salt bridge/hydrogen bond interactions would be lost when the Arg group is 
replaced with Cys group. This loss of interactions may result in decreased affinity of the enzyme 
towards its cofactor, FMN, which may be the cause of its reduced catalytic efficiency.  
 
 
 
 
 
 
 
 
Figure 11: Active site structure of human PNPO Arg 95 mutated to Cys 
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To test our hypothesis and elucidate the reason behind the loss of catalytic activity in 
hPNPO R95C mutant we expressed and purified the mutant enzyme along with the wild type 
enzyme and performed the following experiments: (1) Kinetic activity assay; (2) FMN binding 
studies; (3) Secondary structure analysis; (4) Thermal stability analysis; (5) Structural studies 
using X-ray crystallography. 
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2.2 Materials and methods:  
A. Cloning and site directed mutagenesis of hPNPO cDNA: The cDNA coding for 
wild type human PNPO (hPNPO) was inserted into the pET28a(+) expression vector by Fike et 
al.
16
 pET28a(+) adds 20 residues to the N terminus of hPNPO. These include six His residues 
which help in purification of the protein by a Ni-NTA resin affinity chromatography. The 
cloning region of pET28a-c(+) is shown in Figure 12. The R95C mutant was made on the cDNA 
coding for the wild type enzyme. A standard protocol mentioned in QuickChange kit from 
Stratagene was followed for the mutagenesis. Wild type hPNPO plasmid was used as the 
template DNA. Primers synthesized by integrated DNA technologies were: Forward: 5’- GGA 
AAA CCC TCT GCT TGC ATG TTG CTG CTG AAG - 3’ and reverse: 3’- CCT TTT GGG 
AGA CGA ACG TAC AAC GAC GAC TTC - 5’. The underlined nucleotides correspond to 
codon changes. The PCR reaction was set up using manufacturer’s recommendations. The PCR 
product was transformed into chemically competent E. coli Rosetta (λDE3)pLysS cells 
(Novagen), where  50 µl of the chemically competent Rosetta cells stored at -80°C were thawed 
on ice for approximately 5 minutes and about 5 µl (~50 ng) of the plasmid was mixed with them. 
The mixture was incubated on ice for about 30 minutes. The cells were then subjected to heat 
shock in a water bath maintained at 42 °C for 75 seconds and the tube was transferred onto ice. 
The cells were allowed to grow in 250 µl SOC medium for one hour at 37 °C. The 
transformation mixture was plated on LB agar plates containing 50 µg/ml of Kanamycin (Fisher) 
and 34 µg/ml of Chloramphenicol (Fisher) and allowed to grow overnight at 37 °C. The 
recombinant plasmid was isolated from these cells by using QIAprep miniprep plasmid 
purification kit from Qiagen. Concentration of the plasmid was determined using A260 nm on UV-
Vis Spectrophotometer.  
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Figure 12: Cloning/expression region of pET28a-c(+)  
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B. Expression and purification of R95C mutant: A single colony from the plate 
containing the mutated recombinant pET28a(+) plasmid transformed in Rosetta cells, was used 
to inoculate 300 ml Luria Bertani (LB) medium containing Kanamycin (40µg/ml), 
Chloramphenicol (34 µg/ml), buffered to pH 7.2 with 100 mM potassium phosphate. This was 
incubated overnight at 37 °C, with shaking at the speed of 200 rpm and the overnight grown 
culture was used to inoculate 6 L of LB medium (similar composition as used before). Cells were 
grown at 37 °C with rotary shaking until the OD600 nm reached 1.0 and then induced with IPTG 
(isopropyl β-D-thiogalactopyranoside) under two sets of conditions: (1) overnight induction with 
50 µM IPTG at 18 °C and (2) induction for five hours with 0.5 mM IPTG at 37 °C. Cells were 
harvested by centrifugation at 5000 rpm for 15 minutes and resuspended in cold 50 mM 
potassium phosphate buffer at pH 7.4, containing 300 mM NaCl, 5 mM 2-mercaptoethanol and 
10 µM FMN. Either 1 mM PMSF (phenyl methyl sulfonyl fluoride) or 2 ml protease inhibitor 
cocktail solution from Sigma was added to the cell lysis buffer as protease inhibitors. All the 
further purification procedures were carried out between 0-4°C. Lysis of the resuspended cells 
was carried out using a French press from Avestin at pressure exceeding 20,000 psi. The cell 
debris were separated from the suspension by centrifugation at 12,000 rpm for 20 minutes. The 
solubility of the mutant enzyme was determined by loading the soluble (supernatant) and 
insoluble (precipitate) fractions onto a 10%  SDS PAGE.    
200 mg of Streptomycin sulphate (Fisher) dissolved in 10 ml of cell lysis buffer was 
added with constant stirring to the supernatant and the solution was centrifuged to remove the 
DNA bound to streptomycin sulfate. A yellowish white precipitate was separated. The clarified 
protein solution was added onto a Ni
+2
-nitrilotriacetic acid (Ni-NTA) column (QIAGEN) (3cm X 
8 cm) pre-equilibrated with 50 mM potassium phosphate buffer (pH 7.4) containing 300 mM 
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NaCl, 5 mM 2-mercaptoethanol and 5 mM imidizole. The column was washed with the 
equilibration buffer until A280 nm of the flow through was below 0.1. The mutant protein was 
eluted by gradually increasing the concentration of imidazole in the equilibration buffer to 150 
mM. Fractions were analyzed by 10% SDS PAGE. Precision Plus Protein Dual Color standard 
from Biorad was used as the protein molecular weight standard. The pure fractions were pooled 
and dialysed against 50 mM potassium phosphate buffer (pH 7.4) containing 5 mM 2-
mercaptoethanol. Concentration of the protein was determined by using molar extinction 
coefficient of 76,760 cm
-1
M
-1
 at 280 nm, which possesses an absorbance of 1.67 for 1 mg/ml 
solution.  
C. Cloning, expression and purification of hPNPO wild type: The wild type was 
cloned in pET28a(+) as mentioned before and transformed in E. coli HMS174 cells, which 
require Kanamycin (50 µg/ml) for selection. The expression and purification procedure of the 
wild type was silimar to that of the mutant, using Ni-NTA affinity chromatography.  
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D. Catalytic activity assay: PNPO with the help of the cofactor, FMN oxidizes PNP or 
PMP to PLP as shown in Figure 4. The activities of the wild-type and R95C mutant enzymes 
were followed using PNP as the substrate. The assays were performed in a water-jacketed, 10 cm 
pathlength cuvette at 37 °C, in 50 mM Tris-HCl buffer at pH 8, containing 10 µM FMN. The 
reaction mixture also contained 1 mM dithiothreitol (DTT). The structure of Tris is shown in 
Figure 13. As the reaction proceeds the product PLP forms aldimine with the amino group of 
Tris in the buffer. This can be followed at 414 nm where the aldimine absorbs maximally with a 
molar absorbance coefficient of 5900 cm
-1
M
-1
. Kinetic constant measurements were carried out 
with fixed concentrations of both the enzymes (mutant and wild type). The substrate PNP 
concentrations were varied between 0.01 to 2 mM. Initial velocities were determined for the first 
60 seconds of the reaction monitored at 414 nm. Km and kcat values were determined from the 
double reciprocal plots of the initial velocities and substrate PNP concentrations.  
 
 
 
 
 
 
 
 
Figure 13: Structure of Tris(hydroxymethyl)aminomethane 
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E. FMN binding study using fluorescence spectroscopy: PNPO uses FMN (Figure 14) 
as a cofactor. Fluorescence of FMN is different in free and protein bound states. Quenching of 
FMN fluorescence upon binding to apo PNPO was followed to determine the dissociation 
constant (Kd) for FMN binding to the wild type and R95C mutant.  
Preparation of apoenzyme: During the course of this study a number of procedures 
were tried to prepare apo PNPO. Initially the procedure described by Di Salvo et al was 
attempted which involved the use of phenyl sepharose column for the removal of FMN.
15, 25
 
Later a procedure descibed by Tsuge and co-workers, which is based on dialysis of the holo 
enzyme against 200 mM potassium acetate buffer at pH 5, containing 2-mercaptoethanol and 1 
M potassium bromide for 12 hours was standardized and used for apo hPNPO preparation.
73
    
Determination of dissociation constant (Kd) of FMN binding to apo enzyme: Apo 
PNPO sample (either wild type or R95C mutant) was added to 50 nM FMN in 50 mM potassium 
phosphate buffer (pH 7.2) containing 1 mM DTT. Excitation wavelength was set at 450 nm with 
excitation slit of 1 nm on a Shimadzu RF-5301 PC. Fluorescence emission spectra for FMN 
between 470 nm to 570 nm with 10 nm emission slit were recorded using 1 cm pathlength quartz 
cell. Kd was calculated based on equation 1, where ∆F/F0 is the fractional fluorescence change at 
525 nm at varying concentrations of apo enzyme, ∆Fmax is the maximum change in fluorescence 
intensity,  [APO] is the total apo enzyme concentration, [FMN] is the total cofactor 
concentration, Kd is the dissociation constant of the equilibrium: APO + FMN  HOLO. The 
Kd values were calculated by plotting ∆F/F0 against concentration of apoenzyme using 
SigmaPlot 11.0. 
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                        = ∆Fmax                                                                                                                   (1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Structure of flavin mononucleotide (FMN) 
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F. Secondary structure analysis using circular dichroism: Circular dichroism (CD) 
spectroscopy is an excellent tool for rapid determination of secondary structure and folding 
characterics of proteins. We used the protein CD spectra to determine if the Arg95 to Cys 
mutation in PNPO has affected its conformation. Both wild type and R95C mutant PNPO were 
diluted in 50 mM sodium phosphate buffer, pH 7 to make 0.1 mg/ml solutions. CD spectra for 
both the samples were recorded on Olis optical spectropolarimeter at room tempertature using a 
0.5 cm cell and the obtained spectra were converted to mean residue ellipticity (molar ellipticity) 
(ϴ), which gives the CD signal per amino acid based on peptide concentration (c), path length of 
the cell (l) and mean residue weight (n) using equation 2. 
                                                                                                                                           (2) 
  
Where,  is the observed ellipticity in degrees and M is the molecular weight of the 
protein. 
Mean residual weight (n) =   
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G. Thermal stability analysis: The three amino acids responsible for intrinsic 
fluorescence of folded proteins are tryptophan, tyrosine and phenylalanine. The most dominant is 
tryptophan which is characterized by bicyclic conjugate system of indole moiety. Tryptophan has 
an absorbance maximum near 280 nm and an emission maximum which is environment 
sensitive. In a non polar environment, for example in hydrophobic core of proteins or in an 
organic solvent, Trp shows an emission maximum near 320 nm; whereas it shifts to near 350 nm 
in a polar environment, for example a solvent exposed Trp in proteins or when dissolved in 
aqueous solvents. Melting temperatures (Tm) of both wild type and R95C mutant of PNPO were 
determined by following the change in tryptophan fluorescence when heated from 20-70 °C and 
the thermal stabilities of both the proteins were compared. Melting temperature is the point on 
the melting curve of a protein where 50% of the protein has denatured. 
Protein samples of wild type and mutant enzymes (3.5 µM) in 50 mM sodium Hepes 
buffer pH 7.2, containing 0.2 µM DTT and 0.1 µM EDTA, were heated from 20-70 °C with a 
heating rate of 5°C per minute using a circulating water bath. Fluorescence spectra of samples at 
all temperatures were recorded on fluorescence spectrophotometer by Photon Technology 
International. The excitation wavelength was set at 280 nm. Emission spectra were recorded 
from 300 to 380 nm with excitation slit of 2.5 nm and emission slit of 5 nm. The change in 
tryptophan fluorescence at 329 nm was noted and a melting curve was plotted. A derivative plot 
of the melting curve was then plotted to determine the melting temperature (Tm) of both the 
proteins. 
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F. Structural determination by X-ray crystallography: All the 100 crystallization 
conditions from Hampton Research  were screened with the mutant enzyme. The protein 
concentration was varied from 7 mg/ml to 27 mg/ml. Purity of the protein was above 90% based 
on SDS PAGE analysis.  
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2.3 Results and discussion:  
A. Site directed mutagenesis, expression and purification of the R95C mutant: 
Expression of the R95C mutant was generally low as observed on the SDS PAGE of the soluble 
(cell lysate) and insoluble (pellet) fractions as explained in Section 2.2.B. Overnight induction 
with 0.05 mM IPTG at 18 °C showed better expression compared to five hours induction with 
0.5 mM IPTG at 37 °C (Figure 15). The pH of 7.2 of the LB medium was found to be critical for 
expression since no expression was observed in unbuffered medium. The mutant enzyme bound 
to the Ni
2+
-NTA column as a yellow band and purification yielded ~90% pure protein as 
observed on SDS PAGE of the fractions collected from the column (Figure 16). The enzyme is 
yellow, although intensity of the color is less compared to the wild type. A280 nm is the result of 
seven Trp residues and nine Tyr residues per subunit of the enzyme. 
 
 
 
 
 
 
 
 
 
30 kDa 
1 2 3 4 5 
Figure 15: SDS PAGE analysis of expression conditions attempted for R95C mutant: (1) 
Marker; (2) Soluble, 18 °C 0.05 mM IPTG; (3) Soluble, 37 °C, 0.5 mM IPTG; (4) Insoluble, 18 °C, 
0.05 mM IPTG; (5) Insoluble, 37 °C, 0.5 mM IPTG 
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More than one closely spaced band was seen on the SDS PAGE of the purified mutant 
enzyme. (Figure 16) Such multiple bands were previously reported with the wild type hPNPO.
16
 
Musayev et al analyzed amino acid sequences of these bands observed on SDS-PAGE of the 
wild type enzyme and showed protease digestion at the N-terminus to be the cause of such 
multiple molecular weight bands. The wild type enzyme has been crystallized with both the full 
length and truncated forms, and the two structures show similar fold.
16
 With the mutant too, the 
enzyme preparation showed such multiple bands even though protease inhibitor was added 
before cell disruption and all the protein purification steps were carried out between 0-4 °C. The 
mutant protein samples stored at 4°C, -20°C and -80°C all showed degradation. The enzymes, 
wild type as well as the R95C mutant, when fresh showed lesser degradation which increased 
over the time. This, however, did not affect the catalytic activity of the enzyme.  
30 kDa 
Figure 16: SDS PAGE of purified hPNPO R95C: Fractions collected after Ni-NTA column 
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B. Expression and purification of wild type hPNPO
16
: The wild type of PNPO cloned 
in E. coli HMS174 cells was expressed with similar induction conditions to that of the R95C 
mutant at 0.05 mM IPTG, overnight at 18 °C at 200 rpm. The protein was purified using Ni
2+
-
NTA column and 10% SDS PAGE showed more than a single band near 30 kDa, indicating 
proteolysis as explained in section 2.3.A (Figure 17). The protein was yellow in color and 
exhibited absorption maxima near 280 nm, 385 nm and 448 nm  (Figure 18). The A280 nm 
corresponds to Trp and Tyr residues whereas A385 nm and A448 nm correspond to the absorption by 
the FMN molecules, one per subunit.   
 
 
 
 
 
 
 
 
 
 
 
Figure 17: SDS PAGE of purified hPNPO wild type: Fractions collected after Ni-NTA column 
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Figure 18: UV-Vis spectrum of hPNPO wild type: Protein exhibits peak at 280 nm whereas FMN 
exhibits peaks near 380 nm and 450 nm; the ratio of A280:A450 is near 7 for pure protein preparation 
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C. Catalytic activity assay: PNPO catalayzes the terminal step in the biosynthesis of 
PLP i.e. conversion of PNP or PMP to PLP. The human enzyme is sluggish with low turnover 
number, 0.19 sec
-1
 for PNP and 0.20 sec
-1
 for PMP. The enzyme has equal affinities for both the 
substrates unlike the E. coli enzyme which has more affinity for PNP than PMP
16
. Enzymatic 
activity measurements of wild type and R95C mutant enzymes were carried out by following the 
formation of aldimine-PLP complex at 414 nm as previously described and Lineweaver-Burk 
plots of initial rates against PNP concentrations were obtained to determine Km and kcat values 
(Table 2) (Figure 19.a and 19.b). For comparative purposes, the table also exhibits Km and kcat 
values for the PNPO R229W mutant as previously reported by Musayev et al.
69
  
 
 
 
 
 
 
 
About 4.8 fold decrease in kcat compared to the wild type was observed in case of the 
R95C mutant; whereas Km value increased ~70 fold in R95C mutant. The catalytic efficiency 
was determined from the Km and kcat values by using Equation 3. 
                                              Catalytic efficiency =                                                                      (3)                     
 Wild type  R95C  R229W
69 
kcat (s
-1
)  0.18     0.02 0.037      0.01 0.04      0.01 
K
m
 (µM) 6.18      0.5 436      35 461     27 
Catalytic 
efficiency (µM
-1
s
-1
) 
0.0219 0.0000841 0.0000864 
Table 2: Kinetic constants for human PNPO* 
*Enzymatic activity was measured by following absorption of PLP-aldimine complex at 
414 nm. Values are average of at least three measurements 
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The kinetic studies clearly indicate significant loss in catalytic efficiency of the enzyme 
after Arg95 is mutated to Cys as indicated by ~341 fold decrease in the catalytic efficiency of the 
wild type enzyme. 
 
 
 
 
 
 
                                                                                          
 
 
 
 
 
 
 
 
Figure 19: Lineweaver-Burk plot representing the catalytic activity of hPNPO: (a) Wild type; 
(b) R95C mutant 
(a)  
(b) 
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D. FMN binding study using fluorescence spectroscopy: The crystal structure of 
PNPO shows presence of cofactor FMN tightly bound in the active site of the enzyme by non-
covalent interactions. (Figure 6) The substrate PNP or product PLP is present at the re face of 
FMN with close hydrophobic contacts between the two molecules.
16, 24, 69
 FMN functions to 
remove electrons from the substrate. Arg 95 contributes to a highly conserved region of the 
active site of PNPO family and is observed to form salt bridge/hydrogen bond interactions with 
the phosphate side chain of FMN. The FMN binding studies were performed to determine if the 
loss of this interaction in case of R95C mutation, as well as change in the electrostatics of FMN 
phosphate binding site leads to attenuation of the affinity of FMN towards the enzyme, which 
may result in the loss of catalytic activity.  
Fluorescence titration experiments were performed to determine the dissociation constant 
(Kd) of the FMN binding equilibrium. Quenching of FMN fluorescence was observed upon 
binding to apo enzyme of PNPO. Of several methods attempted for the preparation of 
apoenzyme, the first method involved passage of the protein through a phenyl sepharose column. 
However, separation of FMN from wild type enzyme was difficult using this method, due to high 
affinity of the cofactor towards wild type enzyme. This led to high dilution and decreased 
activity of the enzyme after reconstitution with FMN. The second method for the preparation of 
apoenzyme involved dialysis of the holo enzyme against buffer of low pH containing high salt. 
Preparation of apo enzyme was confirmed by disappearance of A450 nm and A380 nm peaks. This 
resulted in less dilution of the enzyme. About 90% catalytic activity of the enzyme could be 
recovered with this method after incubation with FMN (1:1). (Table 3) 
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The fluorescence emission spectra of FMN after binding to increasing concentrations of 
apo enzymes of human PNPO are shown in Figure 20. The dissociation constants were 
determined for wild type and R95C mutant enzymes using Equation 1. (Table 4) The R95C 
mutant showed ~15-fold higher dissociation constant for FMN binding compared to the wild 
type enzyme, indicating low binding strength of the mutant for FMN. Dissociation constant of 
FMN towards apoenzyme of R229W mutant is shown in Table 5 for comparative purposes.  
 
 
 
 
 
 [PNP]  
Holo (min
-1
) * Apo (min
-1
)*  
Apo 
Reconstituted 
(min
-1
)*  
Wild type (10µM)  10 µM  0.42  0.0267  0.39  
R95C (10 µM)  2 mM  0.3531  0.0012  0.34078 
Table 3: Initial rates of hPNPO catalytic activity assay (apo and holo comparison) 
* Initial rates obtained by following absorption of aldimine formed between product PLP and 
Tris at 414 nm. 
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Protein  Kd  (nM)
a
  
Wild Type  23.7     3.2 
R95C  354.3    12 
R229W
b
  672      65 
[Apo] (nM)
0 2000 4000 6000

F
/F
-0.8
-0.6
-0.4
-0.2
0.0
Figure 20: Fluorescence emission spectra of FMN upon binding to apo hNPO: Decrease in the 
relative FMN fluorescence emission intensity upon binding to apo forms of PNPO: wild type (●) 
and R95C mutant (○). 
Table 4: Dissociation constants (Kd) for FMN binding to apo human PNPO  
a
 Kd is an average of at least 3 measurements 
Lower Kd values indicate higher affinity 
b
 Reference 69 
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E. Secondary structure analysis using circular dichroism: The circular dichroic 
spectra were obtained for both the wild type and mutant enzyme preparations. There is no 
significant difference observed in the trends of the two proteins. (Figure 21) The mutation of 
Arg95 to Cys thus does not seem to have any significant effect on the secondary structure of 
human PNPO, even though affinity of the enzyme towards its cofactor FMN is diminished.     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Circular dichroism spectra of human PNPO: Wild type (Red), R95C mutant (Blue) 
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F. Thermal stability studies: Thermal stability of the proteins was determined by 
heating the protein samples from 20-70 °C and following the quenching of Trp fluorescence. 
Figure 22 shows change in fluorescence of the wild type and R95C mutant of human PNPO with 
respect to the temperature change. Initially the peak maxima lie near 329 nm and 331nm which 
shift to 340 nm and 341 nm for wild type and R95C mutant respectively, as the protein 
denatures. The ability of the enzymes to refold was determined by cooling the proteins back to 
20°C and collecting spectra at all stages. Figure 23.a and 23.b illustrate the changes in the 
fluorescence spectra before and after the thermal denaturation. The observed denaturations were 
irreversible for both the proteins. The change in fluorescence with varying temperatures was 
determined at 329 nm and melting temperatures (Tm) of the proteins were determined by plotting 
first derivative of the fluorescence intensity values as a function of temperature against 
increasing temperatures (Figure 24). There was no difference observed between the Tm of both 
the proteins (64°C). This indicates that the thermal stability of both the enzymes is similar and 
the mutation of Arg95 to Cys has not affected the protein folding patterns of human PNPO. 
 
 
 
 
 
 
 
Figure 22: Fluorescence spectral changes in human PNPO at increasing temperatures: Wild 
type at 20°C (blue), R95C at 20°C (red), wild type at 70°C (green) and R95C at 70°C (purple) 
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Figure 23: Recovery of protein structure after heating and cooling of hPNPO: a: wild type; b: 
R95C mutant; before heating at 20°C (blue), after heating at 70°C (red) and after cooling back to 
20°C (green) 
a  
b  
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Figure 24: Melting curve of human PNPO: Wild type (blue) and R95C mutant (red) 
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2.4 Conclusions: A homozygous missense mutation of Arg95 to Cys in human PNPO is 
one of the several mutations associated with NEE. Our study with R95C was aimed at 
determining the molecular basis of the reduced catalytic activity of human PNPO exhibited by 
this mutant enzyme. Results indicate that the observed loss of catalytic efficiency of the enzyme 
is due to the reduced affinity of the mutant enzyme towards its cofactor FMN by about 15 fold. 
The diminished binding of FMN to the enzyme may be a result of the probable loss of hydrogen 
bonding interactions between Arg95 and the phosphate side chain of FMN, when the Arg residue 
is replaced by Cys. Similar conclusion was made for the PNPO R229W mutant, where 
replacement of Arg229 by Trp led to decreased affinity of FMN with a concomitant decrease in 
PLP production.
69
 These observations clearly explain why the treatment of NEE with pyridoxine 
was unsuccessful in many cases because of inability of the PNPO to oxidize PNP or PMP to 
form PLP. The current treatment with PLP or PL is appropriate since the other enzyme involved 
in PLP metabolism, PLK, can convert PL to PLP. This study clearly shows that the PLP  made in 
vivo from PL is not enough, indicating that PLK alone is not sufficient to meet the cell’s 
requirements and both the salvage enzymes, PL kinase and PNPO, are necessary to provide PLP 
to activate over 140 different apo vitamin B6 dependent enzymes. 
Although we don’t have crystallographic data, we speculate that the mutation may have 
also led to active site distortion which could decrease the enzyme binding affinity for PNP or 
PMP with a concomitant decrease in catalytic rate.  This is consistent with the crystallographic 
structure of R229W mutant that showed significant distortion of the PNP binding site due to the 
mutation leading to reduced PNP binding affinity.   
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Chapter 3 
Mechanism of transfer of pyridoxal 5’-phosphate from pyridoxine 
5’-phophate oxidase to vitamin B6 dependent enzymes 
3.1 Introduction: PLP, a cofactor for many vitamin B6 dependent enzymes is highly 
reactive owing to its aldehyde functionality. As a result the cell has devised several regulatory 
mechanisms that keep the concentration of free PLP very low.  Nevertheless, apo PLP dependent 
enzymes manage to get enough supply of the cofactor. It is thus very intriguing to determine the 
mechanism by which the PLP produced by the salvage enzymes PNPO and PLK is transferred to 
the apo vitamin B6 enzymes. There are two possible mechanisms for the transfer of PLP to apo 
B6 enzymes (Section 1.9). These include direct channeling from PNPO/PLK to apo B6 enzymes 
or release of PLP from PNPO/PLK into the solution in the cell which is then taken up by apo B6 
enzymes. Our research is specially focussed on PNPO and this chapter consists of three 
individual but interrelated techniques used to determine the mechanism of PLP transfer from 
PNPO to vitamin B6 dependent enzymes. These include affinity pull down and fluorescence 
polarization techniques to determine whether PNPO makes physical and specific interactions 
with B6 enzymes and the kinetic studies of PLP transfer from PNPO to apo-SHMT. 
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3.2 Materials and methods:  
3.2.A Expression and purification of proteins: The proteins used to study the 
mechanism of PLP transfer included PNPO from human as well as E. coli as the enzyme 
involved in the biosynthesis of PLP. The vitamin B6 dependent enzymes that were used include 
serine hydroxymethyl transferase (SHMT) from rabbit and E. coli and E. coli aspartate 
aminotransferase (eAAT). The enzymes were expressed, purified and prepared as previously 
reported, with some modifications.
15, 16, 64, 74, 75
 
(a) Human PNPO: The enzyme was expressed and purified as outlined in Section 
2.2.C.
16
  
(b) E. coli PNPO: The protocol for the expression and purification of the dimeric E. coli 
PNPO (M.W. ~50 kDa) has been reported by Di Salvo et al
15
. The gene was cloned in 
pET22b(+) vector (Novagen) which was transformed in E. coli HMS174(DE3) strain (Novagen). 
The cells were expressed in YT (Yeast, Tryptone) medium containing 100 µg/ml of ampicillin 
and induced at 0.5 mM IPTG with shaking at 30°C for 5 hours. The cells were then harvested by 
centrifugation and lysed in 50 mM Tris buffer, pH 8 containing 2 mM EDTA using Avestin cell 
disrupter. The lysed cells were subjected to ammonium sulfate precipitation (25% followed by 
55%) and dialysed against 20 mM potassium phosphate buffer, pH 6.8, containing 5 mM 2-
mercaptoethanol and 0.2 mM EDTA to remove salt. The protein solution was then loaded on 
Sephadex CM-50 column (2.5 X 11 cm) preequilibrated with the dialysis buffer. Wash buffer 
was same as the equilibration (or dialysis) buffer and the column was washed until A280 nm of the 
eluate was below 0.2. The protein was eluted from the column as a yellow band using a linear 
gradient of 100 ml equilibration buffer and 100 ml of 20 mM potassium phosphate buffer (pH 
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6.8) containing 400 mM NaCl, 5 mM 2-mercaptoethanol and 0.2 mM EDTA. The protein was 
then concentrated by 60% ammonium sulfate, desalted by dialysis and loaded onto a ceramic 
hydroxylapatite column (2.5 X 7.5 cm) preequilibrated with 50 mM potassium phosphate of pH 
6.8 containing 5 mM 2-mercaptoethanol and 0.2 mM EDTA, for further purification. The protein 
was eluted using a linear gradient of equilibration buffer and 400 mM potassium phosphate 
buffer pH 6.8 containing 5 mM 2-mercaptoethanol and 0.2 mM EDTA. The protein purity was 
assessed using 10% SDS PAGE and was stored at -80°C with 10% glycerol. 
Activity assay: The enzyme was assayed by following the formation of Tris-PLP 
aldimine complex at 414 nm as described in Section 2.3.C. 
(c) SHMT from rabbit liver cytosol: SHMT belongs to Fold type I of the vitamin B6 
dependent enzymes. The rabbit liver enzyme is a tetramer with molecular weight of 52 kDa per 
monomer. The expression and purification protocol for rcSHMT has been reported previously by 
Di Salvo et al.
74
 Gene coding for SHMT cloned in pET22b(+), was transformed into E. coli 
HMS174(DE3) cells. A single colony of the cells was used to inoculate 100 ml of LB medium 
containing 100 µg/ml of ampicillin. The inoculated medium was allowed to grow overnight at 
37°C with shaking and was then used to inoculate 6 litres of LB medium buffered to pH 7.3 
containing 100 µg/ml of ampicillin. The bacteria were allowed to grow at 37°C with shaking and 
after the OD600 nm reached near 1.8, IPTG was added to the final concentration of 0.5 mM and 
aeration continued for another 4 hours. The cells were harvested by centrifugation at 5000 rpm 
for 15 minutes. The cell pellet was resuspended in 20 mM potassium phosphate buffer, pH 7.3, 
containing 0.1 mM PLP, 5 mM 2-mercaptoethanol and 0.1 mM EDTA. The cells were lysed 
using Avestin cell disrupter and the debris was removed by centrifugation at 12,000 rpm for 25 
minutes at 4°C. Ammonium sulfate was then added to the supernatent to 55% saturation. The 
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precipitated protein was redissolved in 20 mM potassium phosphate buffer, pH 7.3 containing 
PLP, 2-mercaptoethanol and EDTA as described above and dialysed against the same buffer to 
remove ammonium sulfate.  
The protein solution was loaded onto a Sephadex CM-50 column (8 X 15 cm) 
equilibrated with the dialysis buffer of pH 6.8. The protein was bound at the top of the column as 
a yellow band. The column was washed with the equilibration buffer until A280 nm reached below 
0.2. A linear gradient of the equilibration buffer and 300 mM potassium phosphate buffer, pH 
7.3 containing 2-mercaptoethanol and EDTA was used for elution. The enzyme was eluted near 
the end of the gradient and those fractions showing A278 nm/A428 nm near 7 were pooled together. 
The protein was then precipitated by ammonium sulfate to 60% saturation and redissolved in 20 
mM potassium phosphate buffer, pH 7.3 containing 0.1 mM PLP, 5 mM 2-mercaptoethanol and 
0.1 mM EDTA. The protein solution was dialysed against the same buffer without PLP.  
The dialysed enzyme was loaded onto a column of ceramic hydroxylapatite (5 X 7 cm) 
equilibrated with 20 mM potassium phosphate buffer, pH 7.3, containing 5 mM 2-
mercaptoethanol. The column was washed with the equilibration buffer until the A280 nm of the 
flow through was below 0.1. Elution was done with a linear gradient of equilibration buffer and 
300 mM potassium phosphate buffer, pH 7.3, containing 0.1 mM PLP and 5 mM 2-
mercaptoethanol. The collected fractions having A280/A260 ratio more than 7 were pooled 
together. The protein was concentrated by 60% ammonium sulfate precipitation followed by 
dialysis against 20 mM potassium phosphate buffer, pH 7.3, containing 5 mM 2-mercaptoethanol 
and 0.05 mM PLP. Protein purity was assessed using 10% SDS PAGE. Concentration of the 
protein was determined by measuring A280 nm (1 mg/ml solution of the protein giving absorbance 
of 0.72). 
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Activity assay: SHMT has many substrates such as serine, glycine and allothreonine, of 
which, allothreonine was used as a substrate to asses the catalytic activity of the enzyme. 
Acetaldehyde is the product of action of SHMT on allothreonine. This acetaldehyde, in presence 
of excess of alcohol dehydrogenase and NADH is converted to ethanol with subsequent 
oxidation of NADH to form NAD. A340 nm was followed where NADH absorbs and which 
gradually reduces when NADH is consumed as the reaction proceeds.
74
 
 (d) SHMT from E. coli:
75
 pBR322 plasmid containing glyA gene coding for SHMT 
(monomeric M.W. 45 kDa) was transformed into E. coli GS245 cells. A single colony from LB 
agar plate containing 100 µg/ml of ampicillin was incubated into LB medium containing 100 
µg/ml ampicillin and grown overnight at 37 °C with shaking. This culture was then used to 
inocluate 6 litres of LB medium buffered to pH 7.4 containing 100 µg/ml ampicillin and 0.4% 
glucose. The cells were allowed to grow at 37°C with vigorous shaking until OD600 nm reached 
near 1. The bacterial cells were then harvested by centrifugation at 13,000 rpm for 15 minutes. 
The pelleted cells were resuspended in 10 mM Tris HCl buffer, pH 8 containing 1 mM EDTA 
and cell lysis was carried out in Avestin cell disrupter. The protein was subjected to ammonium 
sulfate precipitation (50% followed by 75%) and the protein pellet obtained was dialysed against 
20 mM potassium phosphate buffer pH 7.2, containing 0.1 mM PLP and 1 mM EDTA. The 
protein solution was then loaded onto a DEAE-Sephadex column (12 X 18 cm) pre-equilibrated 
with 20 mM potassium phosphate buffer pH 7.2 containing 0.1 mM PLP and 1 mM EDTA. The 
column was washed with the equilibration buffer until A280 nm of the flow through was below 0.2, 
after which the protein was the eluted with a linear gradient of equilibration buffer and 20 mM 
potassium phosphate buffer, pH 6.4 containing 300 mM NaCl. The enzyme moved down as a 
yellow band and the fractions containing activity were pooled together. After 75% ammonium 
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sulfate precipitation, the protein pellet was dialysed against against 20 mM BES buffer, pH 7 
containing 0.1 mM PLP.  
This was followed by purifying the protein further using a 5 X 6 cm hydroxylapatite 
column. 20 mM BES, pH 7 was used as the equilibration and wash buffer. The enzyme was 
eluted using a linear gradient of the equilibration buffer and 100 mM potassium phosphate 
buffer,  pH 7. The protein was then loaded onto a TMAE column for further purification if 
necessary. Enzyme purity was assessed using 10% SDS PAGE of the fractions collected after the 
final column. 
Activity assay: Assay procedure was similar to rabbit SHMT, using allothreonine as a 
substrate.  
(e) Pyridoxal phosphatase from human brain:
62
 PLP phosphatase (M. W. 64 kDa) was 
cloned on the expression vector pET-19b and transformed into E. coli Rosetta (DE3) pLysS 
cells. The transformants were grown at 37 °C overnight in 200 ml LB medium with 100 µg/ml 
chloramphenicol and 100 µg/ml kanamycin. This grown culture was used to inoculate 6 L LB 
medium containing 100 µg/ml chloramphenicol and 100 µg/ml kanamycin and was grown to 
A600 nm of 0.6. Induction was carried out overnight with 0.05 mM IPTG at 18 °C. The cells were 
harvested, washed and resuspended in 50 mM sodium phosphate buffer, pH 8, containing 300 
mM NaCl and 5 mM imidazole and lysed using Avestin cell disrupter. Lysate was cleared by 
centrifugation at 12,000 rpm at 4 °C for 15 minutes. The supernatent was loaded on Ni-NTA 
column pre-equilibrated with 50 mM sodium phosphate buffer, pH 8, containing 5 mM 
imidazole. Elution buffer contained 50 mM imidazole in 50 mM sodium phosphate buffer, pH 8. 
Purity of the eluted protein was assessed using 10% SDS PAGE. 
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Activity assay:
62, 80
 The assay of PLP- phosphatse activity was carried out in 1 cm 
thermostated cuvette in Agilent 8454 spectrophotometer at 37
0
C by following decrease in OD388 
nm, which indicates dephosphoryalation PLP to PL. PLP-phosphatse  (about 20 μg) was taken in 
20 mM sodium BES buffer, pH 7 containing 4 mM MgCl2. The reaction was started by addition 
of the substrate PLP at concentration of 100 μM and decrease in OD at 388 nm was recorded for 
60 seconds. 
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3.2.B Methods used to determine the mechanism of transfer of PLP from PNPO to 
vitamin B6 dependent enzymes: 
(a) Affinity pull down assay 
Pull down assay is a qualitative in vitro method often used to determine physical 
interactions between proteins. Usually one of the proteins is tagged (called as bait) and the 
second one is called as the prey protein which is untagged. In a typical pull down assay the 
tagged bait protein is captured on an immobilized affinity ligand specific for the tag. The prey 
protein, either alone or in a cell lysate with other proteins, is then allowed to pass through the 
ligand bound bait protein. The unbound protein is washed and the complex between bait and 
prey protein (the protein-protein interaction) is eluted. Pull down assays are employed for 
purposes such as to confirm a previously suspected interaction between two proteins in which 
case the prey protein is expressed in an artificial protein expression system and is passed alone 
from the affinity ligand bound with the bait protein. On the other hand these assays could be used 
to discover unknown interactions between proteins. 
The proteins of our interest are human PNPO and the Fold type I vitamin B6 dependent 
enzyme, SHMT from rabbit liver cytosol. Human PNPO was used as the bait protein. The 
protein has six His residues at the N-terminus and therefore we used Ni-NTA as the affinity 
ligand. SHMT on the other hand has no tag and thus became the prey protein. The two proteins 
were mixed in equimolar concentrations (200 µM) to make about 200 µl of reaction mixture. The 
reaction mixture was incubated on ice for about 5 minutes. Approximately 500 µl of Ni-NTA 
slurry was packed on a column (0.5 X 1 cm) and equilibrated with 50 mM potassium phosphate 
buffer (pH 7.4) containing 5 mM imidazole, 5 mM 2-mercaptoethanol and 300 mM NaCl. The 
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protein mixture was loaded on the column slowly, which bound as a yellow band. The column 
was washed with the equilibration buffer until the A280 nm of the flow through was below 0.2. 
Equilibration buffer containing 150 mM imidazole was used as the elution buffer. Both the 
enzymes, human PNPO and rc SHMT were subjected to the same procedure individually, to 
serve as controls. As another control, the experiment was carried out with a mixture of human 
PNPO and a non-vitamin B6 dependent and non-His tagged protein, lysozyme. The flow through 
and eluates in all the above mentioned sets of experiments were collected and anaylsed using 
SDS PAGE.  
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(b) Determination of Kd by fluorescence polarization 
Fluorescence polarization (FP) measurements have been used in analytical and clinical 
chemistry and as a biomedical research tool for studying membrane mobility, domain motions in 
proteins and interactions at molecular level. Several FP based immunoassays are used in clincal 
chemistry.
76
  
When a small fluorescent molecule, called as tracer or ligand, is excited with plane 
polarized light, the emitted light is highly depolarized, due to tumbling of the tracer molecule. If 
the tracer is bound by a larger molecule its effective motion decreases and due to this reduced 
tumbling, the emitted light becomes more polarized (Figure 25). A fluorescence polarization 
instrument measures the binding interactions between proteins by monitoring changes in the size 
of the fluorescently labelled or inherently fluorescent molecules. We employed the technique to 
study and quantify the molecular binding interactions between PNPO and some vitamin B6 
dependent enzymes, including rabbit SHMT (rSHMT), E. coli SHMT (eSHMT) and E. coli 
aspartate aminotransferase (eAAT).       
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Labelling of human PNPO: Human PNPO was selected as the molecule to be tagged 
and fluorescein 5-maleimide (FMi) (Invitrogen) was used as the fluorescent tag (Figure 26). FMi 
is a fluorescent molecule that reacts predominantly with sulfyhdryls at pH between 6.5 to 7.5 
forming stable thioether bonds. Since PNPO does not have any sylfhydryl residues at the active 
Figure 25: Principle of fluorescence polarization 
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site, tagging with FMi does not hamper its catalytic activity. 50 µM human PNPO was mixed 
with 1 mM FMi in 1 ml of 50 mM sodium HEPES buffer, pH 7.55 containing 150 mM KCl and 
0.01% Triton. The reaction was allowed to occur overnight at 4 °C in the dark. The reaction 
mixture was then centrifuged and the supernatant dialyzed against the same buffer in dark 
overnight to remove the excess dye. The tagged protein was stored at -20°C in amber colored 
container when not in use. The degree of labelling was determined by using equation 4. Catalytic 
activity of the protein was assessed before and after labelling by the assay procedure explained in 
section 2.2.D, to determine if labelling interferes with the activity of human PNPO.  
 
                                                                                                                          (4) 
 
Amax is A495 nm and ε’ is the molar extinction coefficient of FMi, which is 68,000 M
-1
 cm
-1
.  
 
 
 
 
 
 
Figure 26: Fluorescein maleimide 
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Preparation of enzyme solution: The vitamin B6 enzymes and controls were dialyzed 
against 50 mM sodium HEPES buffer, pH 7.55 containing 150 mM KCl and 0.01% Triton (100 
X) overnight at 4 °C prior to use. 
Fluorescence polarization assay: The assay was performed using Tecan Polarion. The 
excitation wavelength was set at 495 nm and emission wavelength at 535 nm. 0.1 µM of tagged 
human PNPO was added to separate wells in a 96 well round bottom polystyrene opaque plate 
Model # 3792 by Corning Inc. The vitamin B6 dependent enzymes were added to the wells at 
concentrations ranging from 0-20 µM. The plate was incubated at 25 °C. Fluorescence 
polarization of the protein mixtures in all the wells was determined at every 5 minutes interval 
for up to 60 minutes. The polarization values were obtained by using Microsoft Excel interfaced 
with the polarimeter. The polarization values in mP were plotted against varying concentrations 
of vitamin B6 dependent enzymes. Binding data between human PNPO and vitamin B6 
dependent enzymes was fitted and analyzed using SigmaPlot 11. Kd value calculations were 
determined based on the principle that the measured polarization signal in mP is a weighted sum 
of the free ligand signal and bound ligand signal using equation 5  
 
                                                                                                                                (5) 
  
Where, Pobs stands for the observed polarization value; PFMI-PNPO is the polarization value 
of tagged PNPO; PFMI-PNPO-E is the polarization value of tagged PNPO with PLP-dependent 
enzyme, when all the PNPO was in the complexed form; [FMI-PNPO] and [FMI-PNPO-E] are 
the concentrations of uncomplexed and complexed tagged PNPO respectively. 
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The equation to determine Kd (Equation 6) was obtained from equation 5 by assuming 
that,  
                                 FMi-PNPO + E    FMi-PNPO-E.  
 
                                                                                                                              (6) 
                                                                                                                              
Pobs is the observed polarization value; P0 is the polarization value in the absence of B6 
dependent enzymes; Pmax is the maximum polarization value obtained upon addition of B6 
dependent enzymes; Kd is the dissociation constant of the interaction between the proteins (an 
indicator of affinity between the proteins) and [E] is the concentration of B6 dependent enzymes.  
As a control, binding curves of non-vitamin B6 dependent enzymes, lactate 
dehydrogenase (LDH) and lysozyme with human PNPO were also obtained.  
 
 
 
 
 
 
 
 
61 
 
(c) Kinetic studies of PLP transfer 
SHMT catalyses many biochemical reactions as mentioned in Section 3.2.2, one of which 
is conversion of glycine to serine, where tetrahydrofolate (THF) serves as a co-substrate and 
functions as a 1-C carrier. In this reaction the PLP bound to SHMT forms a quinonoid complex 
with glycine and THF that absorbs between 490 to 495 nm.
77-79
 We used this property of the 
ternary complex formed between enzyme bound PLP, glycine and THF to determine the kinetic 
profile of addition of PLP from a complex of PNPO-PLP to apo SHMT. 
Preparation of PNPO-PLP complex: PNPO from human as well as E. coli was used for 
this experiment. Both the enzymes were prepared freshly by the procedure mentioned in Sections 
2.2.C and 3.2.B respectively. PLP was obtained from Sigma. 300 µM of PNPO was mixed with 
900 µM PLP. The ratio of 1:3 for PNPO:PLP was always maintained while preparing the 
complex. The mixture was incubated at 25°C for 30 minutes and the excess PLP was removed by 
dialysing the mixture overnight at 4°C against 50 mM sodium BES buffer, pH 7 containing 5 
mM 2-mercaptoethanol, with two buffer changes. After dialysis the mixture was loaded on a gel 
filtration column of Sephadex G50 (0.6 X 45 cm), pre-equilibrated with 20 mM sodium BES 
buffer pH 7, containing 5 mM 2-mercaptoethanol. The complex mixture bound to the column as 
a dark yellow band. The column was then washed with equilibration buffer to elute the complex 
free from any unbound PLP.   
Determination of stoichiometry of PLP binding to PNPO: Two methods were 
employed for the determination of stoichiometry of PLP binding to PNPO. In the first method, 
PNPO (15 µM) complexed with PLP was diluted 10 times in 50 mM sodium BES buffer pH 7, to 
the final volume of 1000 µl. NaOH was added to the diluted complex to the final concentration 
 
62 
 
of 0.1 M in order to inactivate the enzyme and release the bound PLP. The concentration of the 
released PLP was determined using molar extinction coefficient of 6600 M
-1
cm
-1
 and it was 
compared to concentration of the protein. The second method involved determining 
concentration of PLP released from PNPO, based on the activation of apo-SHMT to holo-
SHMT, and comparing it with the concentration of PNPO determined by A280 nm. This method 
took advantage of a unique absorption maximum at 491 nm upon formation of an abortive 
ternary complex of holo-SHMT, glycine and THF, as explained earlier. 30 µM of apo-eSHMT 
was titrated with varying concentrations of free PLP at 37 °C in presence of glycine (50 mM) 
and THF (100 µM) in 50 mM sodium BES buffer, pH 7. A linear standard plot of A491 nm versus 
concentration of free PLP was obtained based on the activation of apo-eSHMT. Freshly prepared 
complexes of human and E. coli PNPO-PLP (30 µM, based on A280 nm) were diluted 5-fold into 
0.1 M NaOH, which denatured the enzyme under basic conditions and released bound PLP. 350 
µl of 100 mM sodium BES of pH 6.5 was added to the protein mixture, to neutralize the pH. 
Activation of 30 µM apo-eSHMT was carried out with this reaction mixture in presence of 
glycine and THF in 50 mM sodium BES buffer, pH 7. The concentration of released PLP was 
calculated by extrapolating from the final absorbance at 491 nm, using the linear standard plot 
and compared to the concentration of PNPO.  
Catalytic activities of PNPO and PNPO-PLP complex: The enzymatic activities of 
200 µg of both human and E. coli enzymes were measured as per the procedure mentioned in 
Section 2.3.C, where formation of aldimine between product PLP and Tris in the buffer was 
followed at 414 nm.
15
 200 µg of both the proteins with stoichiometrically bound PLP were then 
assessed for catalytic activities using the same procedure.  
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Preparation of apo-SHMT:  Apo enzymes of SHMT from rabbit and E. coli were 
prepared by a previously reported method, with minor modifications.
75
 Approximately 280 µM 
of holo SHMT was mixed with 0.5 mM EDTA, 1 mM DTT, 200 μM D-alanine and 200 μM 
ammonium sulfate, in 50 mM potassium phosphate buffer, pH 7. This mixture was incubated at 
37 °C with shaking at 150-180 rpm until the yellow color of the holo enzyme disappeared, which 
indicated removal of PLP from holo-SHMT converting it into apo. This mixture was then 
dialyzed at 4 °C against 50 mM potassium phosphate buffer, pH 7.5 containing 0.5 mM EDTA 
and 1 mM DTT. Concentration of apo enzyme was determined from A280 nm. The prepared apo 
enzyme was stored in aliquots with 10% glycerol at -80 °C if not in use.  
    Transfer of PLP from PNPO-PLP complex to apo-SHMT: Activation of apo-
SHMT to holo after transfer of PLP from PNPO-PLP complex was followed at 491 nm, where 
the ternary complex between glycine, THF and PLP bound to SHMT absorbs maximally. All the 
reactions were carried out at 37 °C in a 1 cm pathlength thermostated cuvette. 20 µM apo-SHMT 
(either E. coli or rabbit), 50 mM glycine and 100 µM THF were added to 50 mM sodium BES 
buffer, pH 7. Reaction was started by addition of 20 µM of PNPO-PLP and the activation of 
SHMT was followed at 491 nm for 15 minutes. Controls were run with 20 µM of free PLP as the 
source of PLP. In another set of experiments, 3 µM PLP specific phosphatase was added to the 
reaction mixture prior to addition of PNPO-PLP complex or free PLP. The activation profiles in 
presence and absence of 3 µM PLP phosphatases were obtained for comparison.  
Test for half site chanelling: 20 µM apo-eSHMT, 50 mM glycine and 100 µM THF 
were taken in 50 mM sodium BES buffer, pH 7. Activation reaction of apo-eSHMT was started 
by addition of 20 µM ePNPO-PLP complex at 37 °C, as mentioned earlier. The reaction was 
followed until it reached saturation (15 minutes). 20 µM of free PLP was then added to this 
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reaction mixture and progress of the reaction was followed at 491 nm for another 10 minutes. 
The same experiment was repeated with  20 µM free PLP replacing ePNPO-PLP complex, as a 
control. Activation profile of eSHMT was obtained by plotting A491 nm versus time. 
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3.3 Results and discussions:  
3.3.A Expression and purification of proteins: All the enzyme preparations were pure, 
when observed on 10% SDS PAGE of the fractions collected after column purification (Figure 
27 a, b, c, d).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
a  b  
c  d  
Figure 27: SDS PAGE of fractions collected after column purification: (a) human PNPO, (b) E. 
coli PNPO, (c) E. coli SHMT and (d) rabbit SHMT 
25 KDa  
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3.3.B Determination of mechanism of PLP transfer from PNPO to vitamin B6 
dependent enzymes:  
(a) Affinity pull down assay 
The pull down assay was used to determine qualitatively an interaction between human 
PNPO and rabbit SHMT. Figure 28 shows a picture of the SDS PAGE of the fractions collected 
after the proteins were loaded onto Ni-NTA as mentioned in Section 3.2.A.I. Lane 1 shows 
resolution of SDS PAGE ladder (Biorad). Lanes 2 and 3 represent elution profiles of 200 µM 
rSHMT. Since rSHMT is not His-tagged, the protein did not bind to the Ni-NTA column and 
was eluted out with the equilibration buffer containing 5 mM imidazole (Lane 2). No protein was 
eluted out with buffer containing 150 mM imidazole (Lane 3). Lanes 4 and 5 represent binding 
of 200 µM of human PNPO. Human PNPO bound to Ni-NTA tightly due to the six His residues 
at the N terminus and therefore was not eluted out with the buffer containing 5 mM imidazole 
(Lane 4). Increase in imidazole concentration in the buffer to 150 mM eluted out all of the 
protein (Lane 5). Elution profile for the equimolar mixture of human PNPO and rSHMT is 
represented by lanes 6 and 7. Some rSHMT was eluted out with 5 mM imidazole in the buffer 
(Lane 6); whereas passing the buffer containing 150 mM imidazole through the column showed 
both human PNPO and rSHMT in the eluate (Lane 7). This indicates that there was some 
interaction between human PNPO and rSHMT due to which the latter remained onto the column 
even though it is not His tagged. 
The experiment was repeated with the non His tagged and non vitamin B6 dependent 
enzyme lysozyme as a control. Figure 29 shows a picture of SDS PAGE of the fractions 
collected from the Ni-NTA column. Lane 1 represents resolution of gel marker (Biorad). Lanes 2 
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and 3 indicate the elution profiles of lysozyme alone. Lysozyme being a non His tagged protein, 
all of the protein loaded on the Ni-NTA column was eluted out at 5 mM imidazole in the wash 
buffer (Lane 2). When the concentration of imidazole in the buffer was increased to 150 mM, 
insignificant amount of imidazole eluted out (Lane 3). This slight binding observed to Ni-NTA 
in lane 3 may be due to the high non-specificity of lysozyme. When equimolar mixture of 
lysozyme and human PNPO was loaded onto Ni-NTA column (Lanes 4 and 5), almost all of the 
lysozyme was eluted at 5 mM imidazole in the buffer (Lane 4). On the other hand elution of the 
mixture with buffer containing 150 mM imidazole showed band corresponding to human PNPO 
only, indicating no interaction between lysozyme and human PNPO (Lane 5). The result further 
confirmed the interaction between PNPO and SHMT to be specific to vitamin B6 dependent 
enzymes. 
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7 6 5 4 3 2 1 
Figure 28: Pull down experiment with hPNPO and rSHMT: SDS PAGE analysis of fractions 
collected from Ni-NTA column (1) Marker; (2) rSHMT wash; (3) rSHMT elution; (4) hPNPO wash; 
(5) hPNPO elution; (6) Mixture wash; (7) Mixture elution 
1 2 3 4 5 
Figure 29: Pull down experiment with hPNPO and lysozyme: SDS PAGE of fractions collected from 
Ni-NTA column: (1) Marker; (2) Lysozyme wash; (3) Lysozyme elution; (4) Mixture wash; (5) Mixture 
elution 
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(b) Determination of Kd by fluorescence polarization 
The technique of fluorescence polarization was used to quantify interactions between 
human PNPO and several vitamin B6 dependent enzymes. The degree of labelling of human 
PNPO with FMi was determined from equation 4 and was found to be 1.1 moles of FMi per 
mole of protein. Also, the enzymatic activity of human PNPO before and after labelling was 
determined using assay procedure as mentioned in Section 2.2.D. Table 5 shows the rates for the 
first 60 seconds of the activity assay of both labeled and unlabeled human PNPO. Labelling of 
human PNPO with the FMi dye did not affect the catalytic activity of the enzyme. 
 
 
 
 
 
 
 Titration of FMi tagged human PNPO with various vitamin B6 dependent enzymes 
yields a binding curve of polarization in mP against increasing concentrations of the vitamin B6 
depedndent enzymes (Figure 30). Control experiments were run to determine the binding of 
tagged human PNPO with non-vitamin B6 dependent enzymes, LDH and lysozyme. Saturation 
binding curves of tagged human PNPO with the vitamin B6 dependent enzymes (Figure 31) 
clearly show interactions between the proteins as indicated by increase in polarization value with 
increasing concentrations of the B6 enzymes. On the other hand, no significant change in the 
 Initial rate (min
-1
) 
Untagged human PNPO 
(200 µg) 
0.3659 
Tagged human PNPO  
(200 µg) 
0.36981 
Table 5: Initial rates of hPNPO activity (tagged and untagged enzyme) 
* Initial rates obtained by following absorption of aldimine formed between product PLP and 
Tris at 414 nm. 
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polarization of tagged human PNPO was seen at increasing concentrations of LDH and 
lysozyme. The experiment demonstrates specificity of binding of human PNPO towards various 
vitamin B6 dependent enzymes. The dissociation constants (Kd) for these bindings were 
calculated based on Equation 5 and are tabulated in Table 6. All the three enzymes exhibited 
more or less equal affinity towards hPNPO.    
 
 
 
 
 
 
 
 
 
 
 
 
 
Enzyme  Kd  (µM)*  
rSHMT  0.8 ± 1.2  
eSHMT  1.3 ± 1.4 
AAT  0.3 ± 0.1 
Table 6: Dissociation constants (Kd) for binding of FMi labeled hPNPO with vitamin B6 
dependent enzymes  
* Lower Kd values indicate stronger binding  
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Figure 30: Saturation binding curves by fluorescence polarization: Titration of FMi tagged 
hPNPO with increasing concentrations of: eSHMT (cyan), rSHMT (red), AAT (green), LDH (orange) 
and lysozyme (blue) 
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(c) Kinetic studies of PLP transfer 
Preparation of PNPO-PLP complex: PNPO-PLP complexes were made with human 
and E. coli proteins as mentioned in Section 3.2.B.c.  
Determination of stoichiometry of PLP binding to PNPO: Since FMN intereferes with 
the absorption of PLP at 388 nm, the second method (Section 3.2.B.c) was used to determine the 
stoichiometry of PLP binding to PNPO. In this method a standard curve was used to analyze the 
level of PLP released from PNPO-PLP complex (Figure 31). Concentration of PLP bound to 
PNPO in 30 µM of the complex was determined by extrapolating from the A491 nm of the 
complex on the standard curve. Table 7 indicates the concentration of PLP bound to human and 
E. coli PNPO with the stoichiometry of PLP binding to both, which shows that 1 PLP molecule 
is bound per monomer of PNPO. 
 
 
 
 
 
 
 
 
Figure 31: Stoichiometry of PLP binding to PNPO: The A491 nm readings of the quinonoid complex 
obtained after activation of apo eSHMT by human (blue) and E. coli (red) PNPO-PLP complexes are 
extrapolated on the standard plot 
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[PLP] in the complex 
(µM) 
Stoichiometry of PLP binding 
with PNPO 
 
 
Human PNPO-PLP complex 34 1.13 
E. coli PNPO-PLP complex 36 1.2 
 
Catalytic activities of PNPO and PNPO-PLP complex: Both human and E. coli 
enzymes complexed with PLP were assayed along with their uncomplexed forms as references. 
Table 8 shows the rates of the first 60 seconds of the reaction. There is no significant difference 
in the catalytic activities of the enzymes in complexed and uncomplexed forms.  
 
 
 Enzyme (200 µg) Initial rate (min
-1
)* 
 
Human PNPO 
PNPO 0.3765 
PNPO-PLP 0.3507 
 
E. coli PNPO 
PNPO 0.4231 
PNPO-PLP 0.4113 
Table 7: Stoichiometry of PLP binding to human and E. coli PNPO 
Table 8: Initial rates of the assay of PNPO (Complexed and uncomplexed enzymes) 
* Initial rate of formation of PLP from PNP determined by following formation of aldimine 
between product PLP and Tris from the buffer at 414 nm 
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Transfer of PLP from PNPO-PLP complex to apo-SHMT: Previous studies have 
shown that PLP binds tightly to PNPO and is not removed even after extensive dialysis or 
passage through gel filtration column, consistent with the study reported here
25
. In this study, we 
followed the transfer of this tightly bound PLP from PNPO to apo-SHMT in the absence and 
presence of PLP-dependent phosphatase. The rationale behind this experiment was to determine 
whether the tightly bound PLP in the PNPO-PLP complex is transferable to apo SHMT and also 
to determine whether the transfer occurs by channeling.  
Figure 32 (a) and (b) shows activation profiles of rcSHMT and E. coli SHMT 
respectively with human PNPO-PLP complex. It can be seen that the tightly bound molecule of 
PLP, which did not separate from PNPO even after dialysis or passage through a gel filtration 
column, got readily transferred to apo-SHMT. However, the rate of transfer of PLP in the 
complex form was nearly half of the free form. The experiment was repeated to monitor the 
transfer of PLP from E. coli PNPO-PLP complex to E. coli SHMT. (Figure 33) Results were 
similar to the activation of rcSHMT. It was observed that the transfer of PLP from PNPO-PLP 
complex to SHMT, when both the complex and apo-SHMT were from the same species or from 
different species, did not differ significantly. This indicates that the mechanism of PLP transfer is 
probably similar in all PLP dependent enzymes.  
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a  
b  
Figure 32: Activation profile of apo SHMT with hPNPO-PLP complex: (a) rcSHMT (b) eSHMT; 
free PLP (blue) and PNPO-PLP complex (red). The results are based on at least two measurements. 
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Use of phosphatases: Phosphatases play a vital role in regulating PLP concentration in 
vivo by converting the phosphorylated forms of B6 vitamers: PNP, PMP and PLP back to PN, 
PM and PL respectively and account for one of the main reasons for the low concentration of 
free PLP (~1-3 µM) in the cell.
62
 Since this concentration of free PLP is not enough for 
activating the dozens of apo B6 enzymes, there must be a mechanism for the transfer of PLP 
synthesized by PNPO and PLK to these apo B6 enzymes. Figure 34 represents the two probable 
modes of PLP transfer and how the presence of phosphatase can possibly affect this process. PLP 
phosphatase if present in the reaction mixture would compete with SHMT for the free PLP, thus 
affecting the rate of activation of apo SHMT. However, in case of channeling, the presence of 
Figure 33: Activation profile of eSHMT: With ePNPO-PLP complex(Red); free PLP (blue). The 
results are based on at least two measurements 
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phosphatase would not affect activation profile of SHMT since insignificant amount of PLP 
would be available free in the solution for phosphatase.  
Figures 35 (a) and (b) shows the kinetic profiles for activation of 20 µM rc SHMT with 
20 µM human as well as E. coli PNPO-PLP complexes in presence and absence of 3 µM PLP 
phosphatase. Activation of apo-SHMT with 20 µM free PLP in presence and absence of PLP 
phosphatase was also included as a control. 
Our study shows that in the presence of PLP-specific phosphatase, the activation of 
SHMT with free PLP is almost totally inhibited, while it has no significant effect on the transfer 
of the tightly bound PLP on the oxidase. This shows that phosphatase did not convert the PLP 
back to PL when the complex was used for activation, which indicates that PLP may not be 
released into the solution and remains attached to PNPO until it is transferred to SHMT. 
Channeling, thus, seems to be the probable mechanism for transfer of PLP from PNPO to 
SHMT.      
 
 
 
 
 
 
 
 
78 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Effect of PLP phosphatase on transfer of PLP: (a) in the free form after PNPO releases 
it and (b) complexed to PNPO which gets transferred to apo-SHMT via channeling  
a  
b  
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a  
b 
Figure 35: Activation profile of apo SHMT with hPNPO in presence of PLP phosphatase: (a) apo 
rcSHMT and (b) apo eSHMT activation with hPNPO-PLP complex; free PLP (blue), hPNPO-PLP 
complex (red), complex in presence of phosphatase (green) and free PLP in presence of phosphatase 
(purple) 
 
80 
 
 
 
 
 
 
 
 
 
 
 
Test for half site chanelling: The rate of formation of ternary quinonoid comlpex with 
PNPO-PLP complex was observed to be nearly half as compared to the activation with free PLP 
under the assay conditions. This could be explained by the phenomenon of half site channeling, 
where either one of the interacting enzymes, (PNPO and SHMT) shares only one PLP binding 
site in the interaction, i. e. either PNPO-PLP complex might be sharing only one PLP binding 
site with apo SHMT or SHMT makes only one site available for PLP from the complex. Figure 
37 shows the observed activation profile of eSHMT. The rate of formation of ternary complex 
showed a sharp rise on addition of additional 20 µM of free PLP to PNPO-PLP complex. On the 
other hand addition of free PLP to the reaction with free PLP did not show any difference in the 
Figure 36: Activation profile of apo eSHMT with ePNPO-PLP complex in presence of PLP 
phosphatase: Free PLP (blue), complex (red), complex in presence of phosphatase (green), free PLP 
in presence of phosphatase (purple) 
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rate. This indicates that the transfer of PLP from PNPO-PLP to SHMT possibly occurs via half 
site channeling under the assay conditions in 50 mM sodium BES buffer, pH 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Test for half site channeling: ePNPO-PLP complex (Red); free PLP (Blue) 
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3.4 Conclusions: PNPO interacts with the vitamin B6 dependent enzymes as observed 
from the affinity pull down experiment and the interaction is specific as no interaction was 
observed between PNPO and the non vitamin B6 dependent enzyme, e.g. lysozyme. Furthermore, 
the interaction exhibits nanomolar to submicromolar range of the dissociation constants (Kd) 
between PNPO and B6 enzymes using fluorescence polarization, indicating high affinity between 
the interacting proteins. This supported the possibility of channeling as a probable mechanism of 
transfer of PLP. In order to further investigate the mode of transfer of PLP we performed kinetic 
studies which showed that the PLP from PNPO-PLP complex (which was unremovable during 
extensive dialysis or passage through column) was readily transferred to apo SHMT. This 
transfer was not affected by the presence of PLP phosphatase which indicates the release of free 
PLP into the solution by PNPO is unlikely. The rate of activation by the complex was nearly half 
of free PLP. Addition of free PLP after the activation with complex reached saturation, supports 
the possibility of half site channeling.  
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